Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph M Herman

Showing results (291-300 of 316) with videos related to

Pageof 32
Sort By:
Translational Oncology|September 22, 2018
Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled AnalysisGian Carlo Mattiucci, Alessio G Morganti, Francesco Cellini, et al.
International Journal of Radiation Oncology, Biology, Physics|June 1, 2022
Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic CancerCharles X Wang, Dalia Elganainy, Mohamed M Zaid, et al.
Gastroenterology|September 22, 2018
Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic CancerVincent Bernard, Dong U Kim, F Anthony San Lucas, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 24, 2014
Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancerKatherine Y Fan, Avani S Dholakia, Aaron T Wild, et al.
Science Advances|February 7, 2024
Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cellsJunke Wang, Jessica Gai, Tengyi Zhang, et al.
International Journal of Radiation Oncology, Biology, Physics|June 19, 2013
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancerJoseph M Herman, Katherine Y Fan, Aaron T Wild, et al.
JAMA Surgery|July 13, 2017
Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal AdenocarcinomaJordan M Cloyd, Huamin Wang, Michael E Egger, et al.
Journal of Radiation Oncology|March 11, 2015
Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relationshipsAvani S Dholakia, Amy Hacker-Prietz, Aaron T Wild, et al.
International Journal of Radiation Oncology, Biology, Physics|November 7, 2024
NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiation TherapyNina N Sanford, Amol K Narang, Todd A Aguilera, et al.
Molecular Cancer Research : MCR|August 29, 2013
The twist box domain is required for Twist1-induced prostate cancer metastasisRajendra P Gajula, Sivarajan T Chettiar, Russell D Williams, et al.
Pageof 32

Showing results (291-300 of 316) with videos related to

Sort By:
Pageof 32
Translational Oncology|September 22, 2018
Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled AnalysisGian Carlo Mattiucci, Alessio G Morganti, Francesco Cellini, et al.
International Journal of Radiation Oncology, Biology, Physics|June 1, 2022
Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic CancerCharles X Wang, Dalia Elganainy, Mohamed M Zaid, et al.
Gastroenterology|September 22, 2018
Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic CancerVincent Bernard, Dong U Kim, F Anthony San Lucas, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 24, 2014
Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancerKatherine Y Fan, Avani S Dholakia, Aaron T Wild, et al.
Science Advances|February 7, 2024
Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cellsJunke Wang, Jessica Gai, Tengyi Zhang, et al.
International Journal of Radiation Oncology, Biology, Physics|June 19, 2013
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancerJoseph M Herman, Katherine Y Fan, Aaron T Wild, et al.
JAMA Surgery|July 13, 2017
Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal AdenocarcinomaJordan M Cloyd, Huamin Wang, Michael E Egger, et al.
Journal of Radiation Oncology|March 11, 2015
Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relationshipsAvani S Dholakia, Amy Hacker-Prietz, Aaron T Wild, et al.
International Journal of Radiation Oncology, Biology, Physics|November 7, 2024
NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiation TherapyNina N Sanford, Amol K Narang, Todd A Aguilera, et al.
Molecular Cancer Research : MCR|August 29, 2013
The twist box domain is required for Twist1-induced prostate cancer metastasisRajendra P Gajula, Sivarajan T Chettiar, Russell D Williams, et al.
Pageof 32